';

Tuberculosis

Taking the fight against drug resistance into the community

Utilising ultra-sensitive molecular diagnostics QuantuMDx will be bringing gold-standard diagnostics into the community.

We are working with the Bill and Melinda Gates Foundation to develop technologies for rapid and low cost TB detection and drug susceptibility testing.
The Problem

Healthcare systems face many barriers, including a lack of finance, testing expertise and infrastructure, to the provision of TB diagnostics.

5% of patients with newly diagnosed tuberculosis underwent drug sensitivity testing in 2012
9% of patients with cases being ‘retreated’ underwent Drug Sensitivity Testing in 2012
Increasing resistance to TB drugs and non-adherence due to the incredibly burdensome regimens has led companies to develop new treatments.

Whilst many of these drugs are still undergoing early stage trials, new regimens are expected to be available soon.

However without widespread drug sensitivity testing (DST), which is currently confined to centralised laboratories, inaccessible to many who need it, these drugs will not have full impact.

Increasing resistance to TB drugs and non-adherence due to the incredibly burdensome regimens has led companies to develop new treatments.

Whilst many of these drugs are still undergoing early stage trials, new regimens are expected to be available in 2018.

However without widespread drug sensitivity testing (DST), which is currently confined to centralised laboratories, inaccessible to many who need it, these drugs will not have full impact.

Est 10m new cases in 2017
Est 558,000 people infected with drug resistant TB in 2017
Est 1.6m TB related deaths in 2017

The average total cost incurred by TB patients in low-and middle-income countries is estimated at 20% - 40% of annual family income.

3.6 million cases ‘missed’ by healthcare systems
MDR-TB: multi drug resistant tuberculosis - does not respond to initial treatment
Only 1 in 4 MDR-TB cases diagnosed
3 million cases ‘missed’ by healthcare systems
MDR-TB: multi drug resistant tuberculosis - does not respond to initial treatment
Less than 1 in 4 MDR-TB cases diagnosed

The Solution

QuantuMDx is utilising its superior multiplexing capability to develop a drug susceptibility test for the future drug regimens. We have partnered with FIND to overcome the many challenges of sample preparation.

“It seems almost incredible that during this century and the previous one, a single disease, tuberculosis, was responsible for the deaths of approximately a thousand million human beings.”
FIND
Nonprofit Organization Management

SHARE THIS PAGE

Subscribe to our e-newsletter and keep up to date with QuantuMDx

THE FUTURE OF DIAGNOSTICS

E-NEWSLETTER
Partnerships

Clinical development and trial partners, access to samples.

Global Partnerships, Global Vision
LEARN MORE
  • Diagnostics
    Under the Tree

    Supporting disease eradication efforts with simple and accurate diagnostic testing in the community.

  • Q-POC™
    Portable Diagnostics

    Our portable, battery-operated molecular diagnostic device will provide sample-to-result testing in less than 20 minutes.

  • Internet of Life™
    Networking Disease Data

    Globally distributed Q-POC devices will geotag and anonymise pathogen data, and send it to the cloud for real-time disease and drug resistance monitoring.

Contact

Contact

Contact

  • MENU
logo